Log In
Print
BCIQ
Print
Print this Print this
 

LGT209

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionLipid modulator
Molecular Target Proprotein convertase subtilisin/kexin type 9 (PCSK9)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationHypercholesterolemia
Indication DetailsTreat hypercholesterolemia
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today